Breaking News, Financial News

Financial Report: BASi

Revenues up 17% in the quarter

By: Kristin Brooks

Managing Editor, Contract Pharma

BASi
 
4Q Revenues: $6.4 million (+17%)

4Q Loss: $404,000 (earnings were $252,000 4Q13)

YTD Revenues: $24.6 million (+11%)

YTD Loss: $1.1 million (earnings were $773,000 YTD13)

Comments: Service revenue for the quarter was up 23% to $4.9 million, due to an increase in Preclinical services studies offset slightly by lower Bioanalytical services revenue. Product revenue was flat at $1.5 million. Impairment charges of $374,000 impacted results in the quarter and FY.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters